Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk

Highlights

• High plasma dp-ucMGP is associated with several cardiovascular risk factors.

• Dp-ucMGP could possibly be used as a biomarker of cardiovascular risk.

• The strong association of dp-ucMGP with obesity deserves further investigation.

Abstract

Background

Dephosphorylated uncarboxylated matrix Gla-protein (dp-ucMGP) is a biomarker of functional vitamin K status. High plasma dp-ucMGP concentrations reflect a low vitamin K status and have been related to vascular calcification. Our aims were to assess plasma levels of dp-ucMGP and their association with cardiovascular risk in a general population.

Methods

Plasma dp-ucMGP measurements were performed using the IDS-iSYS InaKtif MGP assay in 491 consecutive participants in a Danish general population study (229 males and 262 females, aged 19–71 years). Multivariable linear and logistic regressions were used to assess the association between dp-ucMGP levels and cardiovascular risk factors.

Results

Mean ± standard deviation (SD) for dp-ucMGP was 465 ± 181 pmol/L, and upper 95th percentile was 690 pmol/L. In logistic regression analyses, an increase in dp-ucMGP category (<300, 300–399, 400–499, ≥500 pmol/L) was positively associated with obesity, odds ratio (OR) 2.27 (95% confidence interval (CI) 1.54–3.33), history of cardiovascular disease, OR 1.77 (CI 1.02–3.05), and above-median estimated pulse wave velocity (ePWV), OR 1.54 (CI 1.21–1.96), when adjusted for age, sex, and lifestyle factors. 1 SD increase in diastolic and systolic blood pressure (BP) corresponded to a 5.5% (CI 2.9–8.0%) and 4.7% (CI 2.1–7.4%) increase in dp-ucMGP, respectively, when adjusted for age and sex.

Conclusion

Plasma dp-ucMGP levels were positively associated with obesity, BP, ePWV, and history of cardiovascular disease. These findings support that dp-ucMGP is a biomarker of cardiovascular risk, and that vitamin K status could play a role in vascular calcification. The strong association with obesity deserves further attention.

Introduction

The classical role of vitamin K in hemostasis was established early in the 20th century [1]. More recently, its role has been expanded to include effects on arterial calcification, bone formation, and regulation of cell growth. This indicates that abnormal vitamin K status may confer an increased risk of several types of diseases, including cardiovascular disease (CVD), osteoporosis, and cancer [2], [3], [4], [5].

Vitamin K exercises its functions through activation of γ-carboxyglutamate (Gla)-containing proteins such as Matrix Gla Protein (MGP). MGP is a vitamin K-dependent mineral-binding protein in the extra-cellular matrix [6]. It is synthesized in vascular smooth muscle cells and chondrocytes [7]. MGP is a potent inhibitor of soft-tissue calcification through hydroxyapatite-absorption, and may thus potentially protect against arterial calcification [8], [9], [10].

Studies of the health effects of vitamin K deficiency have been hampered by difficulties in obtaining accurate data on dietary intake of vitamin K and the lack of reliable biomarkers of vitamin K status [11]. Vitamin K status can be assessed by measuring vitamin K concentrations in plasma, or by determining the amount of inactive vitamin K-dependent proteins [12]. The first method is sensitive to triglyceride concentrations and recent vitamin K intake, and gives little information about tissue-utilization. The second method uses plasma concentrations of different MGP-isoforms as indicators of functional vitamin K concentrations [13]. MGP is post-translationally modified and is inactive in its unmodified form. The protein undergoes two independent modifications: serine phosphorylation and glutamate carboxylation. Glutamate carboxylation is dependent on vitamin K hydroquinone as a co-factor. MGP can therefore exist in an inactive conformation, a fully active phosphorylated and carboxylated conformation, and in two intermediary conformations [14]. The inactive dephosphorylated-uncarboxylated MGP (dp-ucMGP) may be used as a biomarker, where high plasma concentrations reflect a low vitamin K status [15]. Recently, immunoassays for measurement of plasma dp-ucMGP have become commercially available, but published data on dp-ucMGP in the general population is limited.

Two groups of dietary compounds possess vitamin K activity: phylloquinones (K1) and menaquinones (K2). Vitamin K1 is present in all green plants, while vitamin K2 is mainly of bacterial origin and found in fermented foods. Estimated intake of vitamin K varies greatly from country to country, from 230 µg/day in Japan to 70 µg/day in Scotland [16].

Our knowledge about the relationship between dp-ucMGP levels, vitamin K status, and their effects on CVD stems from studies of patients with chronic kidney disease (CKD). Dp-ucMGP levels are increased in CKD-patients compared to non-CKD-patients [12], and dialysis patients exhibit profound vitamin K deficiency [17]. Use of vitamin K antagonists (VKAs) increases dp-ucMGP levels compared to non-users [18], whereas vitamin K supplementation decreases the levels of dp-ucMGP [12], [19]. This suggests that a rise in plasma dp-ucMGP reflects a decrease in vitamin K status and supports the use of dp-ucMGP as a marker for functional vitamin K status.

Several data suggest a link between dp-ucMGP and CVD in CKD-patients, since they have a 30-fold higher incidence of CVD compared to the general population [20], and vascular calcification is highly prevalent in dialysis patients. In contrast, little is known about the effects of vitamin K status on CVD-risk in the general population.

The aim of this study was two-fold. First, to assess plasma levels of dp-ucMGP in a sample from the adult Danish general population. Secondly, to investigate the association between plasma dp-ucMGP, CVD-risk factors, and history of CVD.